RB1 and prostate cancer: Additionally, the research demonstrated that PARPis Olaparib and Talazoparib significantly hamper the growth of prostate cancer cell lines and organoids derived from human mCRPC exhibiting both homozygous and heterozygous co-deletion of BRCA2 and RB1.